Wells Fargo
PCVX icon

Wells Fargo’s Vaxcyte PCVX Stock Holding History

Wells Fargo’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.7M Buy
132,513
+79,407
+150% +$4.31M ﹤0.01% 2429
2026
Q1 		$3.09M Sell
53,106
-80,969
-60% -$4.4M ﹤0.01% 2957
2025
Q4 		$6.19M Buy
134,075
+8,027
+6% +$359K ﹤0.01% 2468
2025
Q3 		$4.54M Buy
126,048
+4,763
+4% +$158K ﹤0.01% 2667
2025
Q2 		$3.94M Buy
121,285
+14,550
+14% +$477K ﹤0.01% 2655
2025
Q1 		$4.03M Buy
106,735
+34,460
+48% +$2.76M ﹤0.01% 2587
2024
Q4 		$5.92M Buy
72,275
+25,257
+54% +$2.51M ﹤0.01% 2300
2024
Q3 		$5.37M Sell
47,018
-2,274
-5% -$205K ﹤0.01% 2298
2024
Q2 		$3.72M Buy
49,292
+6,237
+14% +$425K ﹤0.01% 2486
2024
Q1 		$2.94M Buy
43,055
+7,242
+20% +$501K ﹤0.01% 2666
2023
Q4 		$2.25M Sell
35,813
-24,595
-41% -$1.28M ﹤0.01% 2816
2023
Q3 		$3.08M Sell
60,408
-17,782
-23% -$877K ﹤0.01% 2462
2023
Q2 		$3.9M Buy
78,190
+26,284
+51% +$1.25M ﹤0.01% 2344
2023
Q1 		$1.95M Buy
51,906
+47,945
+1,210% +$2.03M ﹤0.01% 2889
2022
Q4 		$190K Buy
3,961
+2,452
+162% +$96.2K ﹤0.01% 4199
2022
Q3 		$36K Sell
1,509
-377
-20% -$9.56K ﹤0.01% 5099
2022
Q2 		$41K Sell
1,886
-2,063
-52% -$47.7K ﹤0.01% 5115
2022
Q1 		$95K Sell
3,949
-13,910
-78% -$304K ﹤0.01% 5361
2021
Q4 		$425K Buy
17,859
+17,576
+6,211% +$409K ﹤0.01% 4789
2021
Q3 		$7K Sell
283
-125
-31% -$3.03K ﹤0.01% 6305
2021
Q2 		$9K Sell
408
-33,844
-99% -$693K ﹤0.01% 6179
2021
Q1 		$676K Sell
34,252
-1,469
-4% -$37K ﹤0.01% 4511
2020
Q4 		$949K Buy
35,721
+21,924
+159% +$815K ﹤0.01% 4067
2020
Q3 		$681K Buy
+13,797
New +$549K ﹤0.01% 4134

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wells Fargo's PCVX Position: Q2 2026 in Review

Wells Fargo increased its Vaxcyte (PCVX) stake by 150% in Q2 2026, buying an estimated $4.31M and bringing the position to 132,513 shares worth $7.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2429.

Wells Fargo first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Wells Fargo held 132,513 shares of Vaxcyte worth $7.7M as of Q2 2026.
  • Wells Fargo bought 79,407 Vaxcyte shares in Q2 2026, an estimated $4.31M.
  • Vaxcyte made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2429 holding.
  • Wells Fargo first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.